Cancer Res Treat.  2019 Apr;51(2):538-546. 10.4143/crt.2017.591.

Diabetes Medication Use in Association with Survival among Patients of Breast, Colorectal, Lung, or Gastric Cancer

Affiliations
  • 1Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. xiao-ou.shu@vanderbilt.edu
  • 2Tongren Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • 3Shanghai Cancer Institute, Shanghai Jiao Tong University, Shanghai, China.
  • 4Division of General Internal Medicine, Department of Medicine, Vanderbilt University, Nashville, TN, USA.

Abstract

PURPOSE
Studies suggest that regular use of metformin may decrease cancer mortality. We investigated the association between diabetes medication use and cancer survival.
MATERIALS AND METHODS
The current study includes 633 breast, 890 colorectal, 824 lung, and 543 gastric cancer cases identified from participants of two population-based cohort studies in Shanghai. Information on diabetes medication use was obtained by linking to electronic medical records. The associations between diabetes medication use (metformin, sulfonylureas, and insulin) and overall and cancer-specific survival were evaluated using time-dependent Cox proportional hazards models.
RESULTS
After adjustment for clinical characteristics and treatment factors, use of metformin was associated with better overall survival among colorectal cancer patients (hazards ratio [HR], 0.55; 95% confidence interval [CI], 0.34 to 0.88) and for all four types of cancer combined (HR, 0.75; 95% CI, 0.57 to 0.98). Ever use of insulin was associated with worse survival for all cancer types combined (HR, 1.89; 95% CI, 1.57 to 2.29) and for the four cancer types individually. Similar associations were seen for diabetic patients. Sulfonylureas use was associated with worse overall survival for breast or gastric cancer (HR, 2.87; 95% CI, 1.22 to 6.80 and HR, 2.05; 95% CI, 1.09 to 3.84, respectively) among diabetic patients. Similar association patterns were observed between diabetes medication use and cancer-specific survival.
CONCLUSION
Metformin was associated with improved survival among colorectal cancer cases, while insulin use was associated with worse survival among patients of four major cancers. Further investigation on the topic is needed given the potential translational impact of these findings.

Keyword

Cancer survival; Diabetes medication; Metformin

MeSH Terms

Breast*
Cohort Studies
Colorectal Neoplasms
Electronic Health Records
Humans
Insulin
Lung*
Metformin
Mortality
Proportional Hazards Models
Stomach Neoplasms*
Insulin
Metformin

Reference

References

1. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008; 300:2754–64.
2. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012; 7:e33411.
Article
3. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010; 3:1451–61.
Article
4. Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 2013; 37:207–18.
Article
5. Baur DM, Klotsche J, Hamnvik OP, Sievers C, Pieper L, Wittchen HU, et al. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism. 2011; 60:1363–71.
Article
6. Bo S, Ciccone G, Rosato R, Villois P, Appendino G, Ghigo E, et al. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab. 2012; 14:23–9.
Article
7. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010; 33:322–6.
8. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012; 35:299–304.
9. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol. 2012; 23:1771–80.
Article
10. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. 2012; 118:1202–11.
Article
11. Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer. 2012; 131:752–9.
Article
12. Ahmed I, Ferro A, Cohler A, Langenfeld J, Surakanti SG, Aisner J, et al. Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation. J Thorac Dis. 2015; 7:346–55.
13. Lin J, Gill A, Zahm SH, Carter CA, Shriver CD, Nations JA, et al. Metformin use and survival after non-small cell lung cancer: a cohort study in the US Military health system. Int J Cancer. 2017; 141:254–63.
Article
14. Ramjeesingh R, Orr C, Bricks CS, Hopman WM, Hammad N. A retrospective study on the role of diabetes and metformin in colorectal cancer disease survival. Curr Oncol. 2016; 23:e116–22.
Article
15. Paulus JK, Williams CD, Cossor FI, Kelley MJ, Martell RE. Metformin, diabetes, and survival among U.S. Veterans with colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2016; 25:1418–25.
Article
16. Lee CK, Jung M, Jung I, Heo SJ, Jeong YH, An JY, et al. Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy. Ann Surg. 2016; 263:96–102.
Article
17. Lacroix O, Couttenier A, Vaes E, Cardwell CR, De Schutter H, Robert A. Impact of metformin on gastric adenocarcinoma survival: a Belgian population based study. Cancer Epidemiol. 2018; 53:149–55.
Article
18. Ioacara S, Guja C, Ionescu-Tirgoviste C, Fica S, Roden M. Cancer specific mortality in insulin-treated type 2 diabetes patients. PLoS One. 2014; 9:e93132.
Article
19. Bowker SL, Yasui Y, Veugelers P, Johnson JA. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia. 2010; 53:1631–7.
Article
20. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007; 16:241–9.
Article
21. Chaiteerakij R, Petersen GM, Bamlet WR, Chaffee KG, Zhen DB, Burch PA, et al. Metformin use and survival of patients with pancreatic cancer: a cautionary lesson. J Clin Oncol. 2016; 34:1898–904.
Article
22. Xin W, Fang L, Fang Q, Zheng X, Huang P. Effects of metformin on survival outcomes of pancreatic cancer patients with diabetes: a meta-analysis. Mol Clin Oncol. 2018; 8:483–8.
Article
23. Lee SA, Xu WH, Zheng W, Li H, Yang G, Xiang YB, et al. Physical activity patterns and their correlates among Chinese men in Shanghai. Med Sci Sports Exerc. 2007; 39:1700–7.
Article
24. Zheng W, Chow WH, Yang G, Jin F, Rothman N, Blair A, et al. The Shanghai Women's Health Study: rationale, study design, and baseline characteristics. Am J Epidemiol. 2005; 162:1123–31.
Article
25. Centers for Disease Control and Prevention [Internet]. Atlanta, GA: Centers for Disease Control and Prevention;2018. [cited 2018 Jun 1]. Available from: https://www.cdc.gov/nhsn/xls/icd-10-cmddc.xlsxI--CDDC.
26. ICD10Data.com [Internet]. ICD10Data.com;2018. [cited 2018 Jun 1]. Available from: http://www.icd10data.com/ICD10CM/Codes/E00-E89/E08-E13/E11-I--CDCETd.
27. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997; 145:72–80.
28. Hanley JA, Foster BJ. Avoiding blunders involving 'immortal time'. Int J Epidemiol. 2014; 43:949–61.
Article
29. Belda-Iniesta C, Pernia O, Simo R. Metformin: a new option in cancer treatment. Clin Transl Oncol. 2011; 13:363–7.
Article
30. Howlett HC. Metformin in the management of type 2 diabetes. Diabet Med. 1989; 6:179–80.
31. Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer. 2008; 15:833–9.
Article
32. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 2009; 30:586–623.
Article
33. Cao X, Wen ZS, Wang XD, Li Y, Liu KY, Wang X. The clinical effect of metformin on the survival of lung cancer patients with diabetes: a comprehensive systematic review and meta-analysis of retrospective studies. J Cancer. 2017; 8:2532–41.
Article
34. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011; 9:33.
Article
35. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 2008; 110:246–50.
Article
36. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29:254–8.
Article
37. Barker BE, Fanger H, Farnes P. Human mammary slices in organ xulture. I. Method of culture and preliminary observations on the effect of insulin. Exp Cell Res. 1964; 35:437–48.
38. Rosenfeld RG. Insulin-like growth factors and the basis of growth. N Engl J Med. 2003; 349:2184–6.
Article
39. Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat. 1998; 47:111–20.
Article
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr